



To: Medical Staff, Advanced Practice Providers and Nursing Leadership

From: Todd Boyd, DO, MT(ASCP), Medical Director, Department of Pathology and Laboratory Medicine
Jennifer Nichols, MBA, Director, Clinical Laboratory

Date: September 17, 2026

Roche Chemistry Implementation Update

As previously communicated, the Laboratory will be implementing a new testing platform. The first phase of the transition will go live on September 22nd at 0900. The phased approach will allow us to transition testing carefully while maintaining patient-care services and monitoring performance throughout implementation.

The first phase will include the following panels and/or individual tests.

Panels Going Live

- Basic Metabolic Panel
- Comprehensive Metabolic Panel
- Liver Panel
- Renal Panel
- Bilirubin Panel
- Lytes Panel
- Urine Drugs of Abuse Panel

Individual analytes: sodium, potassium, chloride, total carbon dioxide, glucose, blood urea nitrogen, creatinine, calcium, albumin, alkaline phosphatase, total bilirubin, AST, ALT, total protein, phosphorus, indirect bilirubin and direct bilirubin.

Urine Drugs of Abuse Screening Panel: AMP, BARB, BENZ, BUP, THC, COC, FENT, METH, OPI, OXY and PCP.

- ***Note new in-house additions (FENT, METH, BUP, and OXY)***
- ***Confirmatory testing will be sent out if requested for quantification***

Individual Tests Going Live

ACTM - Acetaminophen; SAL - Salicylate; ALC - Alcohol; MG - Magnesium; CRP - C-Reactive Protein; CK - Creatine Kinase, Total; TROPT - Troponin T, TSH, T4- Total Thyroxine, and FT4- Free Thyroxine


What providers should expect

- Turnaround time expectations are not changing.
 - Slight delays may occur during the phased implementation while the Laboratory operates two analyzer systems and directs testing to the appropriate platform.
- Reference ranges updated.
 - Use the updated reference ranges that are displayed with each patient result.
Most reference ranges have changed with the new methodology
- Review results carefully.
 - Use caution when reviewing serial results obtained before and after the transition. Differences may reflect changes in analyzer methodology or reference ranges and may not represent a change in the patient's clinical condition.



See something-say something

If a result, reference range, patient trend or workflow does not appear as expected, please utilize the following QR code to notify the Laboratory promptly so we can investigate.



*****Urgent patient-care concerns: Contact the Laboratory directly by phone*****

Respectfully,
Todd and Jen